Table 2: Changes in acylcarnitine levels (umol/L) with therapy.

Months Lipid therapy C16:0 () C18:0 ( 0.02–0.10) C18:1 () C18:1-OH (# n/a) C2:0 ( 3–23) C3:0 () C total ( 21–70) C free ( 13–56) 1 Nil 1.6 0.84 2.64   21 n/a 95 66 7 Fenofibrate 145 mg + Ezetimibe 10 mg 0.3 0.46 0.14   n/a 0.71 105 91 17 Fenofibrate 145 mg 1.3 1.34 0.72 0.02 13 0.71 86 68 30 Nil 1.8 2.6 0.8 0.80 20 0.80 104 76 33 Fenofibrate 96 mg 1.2 0.44 1.46 n/a 20 0.79 145 119

#: provisional reference interval (umol/L). C16:0: palmitoylcarnitine; C18:0: stearoylcarnitine; C18:1: oleoylcarnitine; C2:0: acetylcarnitine; C3:0: propionylcarnitine; C18:1-OH: hydroxyoleylcarnitine; C total: total carnitine; C free: free carnitine.